Regenerative Patch Technologies - Crunchbase Company Profile & Funding

Overview

Regenerative Patch Technologies

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Regenerative Patch Technologies

CB Rank

419471

Regenerative Patch Technologies LLC, a biotechnology company.

Founded

obfuscation

Private

Palo Alto, California, United States

regenerativepatch.com/

Biotechnology

Key People

Jane Lebkowski: President
Past Role: Regenerative Patch Technologies, President of Research & Development
Mitchell Presnick: Interim CFO
Past Role: ROOM Technology Ventures, Founder, Chief Executive Officer & Board Member

Details

Legal Name

Regenerative Patch Technologies LLC

Operating Status

Active

Company Type

For Profit

About the Company

Regenerative Patch Technologies LLC, a biotechnology company focused on the development of cell-based implant technology for the treatment of retinal diseases announced the publication of preliminary results from its Phase 1/2a clinical trial in dry age-related macular degeneration.

Phone Number

(833) 734-3678

Contact Email

inquiries@regenerativepatch.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

CPCB-RPE1 Implant

A subretinal implant consisting of a monolayer of human embryonic stem cell-derived retinal pigment epithelium (RPE) cells on a synthetic membrane, designed to replace damaged RPE cells in patients with geographic atrophy due to age-related macular degeneration.